AMYLOID DEPOSITION ALZHEIMER'S DISEASE

大脑中的淀粉样蛋白沉积被认为是 阿尔茨海默病，虽然因果关系尚未得到证实。 淀粉样蛋白还没有用于研究，由于实际 它的净化问题。 此外，目前的生物物理方法 不适用于表征不溶性、非结晶性 蛋白质如淀粉样蛋白。 我们的工作集中在这两个方面 问题 我们已经成功地开发了一种合成路线， 蛋白质，这是适合规模扩大。 一种新的生物物理方法 （固态核磁共振和傅立叶变换红外光谱）使我们能够观察淀粉样蛋白的细节， 迄今为止一直未被发现的结构。 我们建议继续 这种方法的发展。 我们的目标是完全确定 淀粉样蛋白的分子结构。 我们也有兴趣利用这些结构信息来设计 结合淀粉样蛋白（刚果红的类似物）和/或抑制 淀粉样蛋白形成（构象受限制的肽类似物）。 最后， 我们希望通过以下方法确定淀粉样蛋白形成的序列要求： 比较各种淀粉样蛋白的序列。

Amyloid deposition in the brain is considered to be a marker for Alzheimer's disease, although a causal relationship has not been proven. The amyloid protein has not been available for study due to practical problems with its purification. In addition, current biophysical methods are not suited for the characterization of insoluble, noncrystalline proteins such as the amyloid proteins. Our work has focussed on these two problems. We have been successful in developing a synthetic route to the 0 protein which is amenable to scale-up. A novel biophysical approach (solid-state NMR and FTIR) has allowed us to observe details in amyloid structure which have heretofore escaped detection. We propose to continue the development of this approach. Our goal is to fully determine the molecular structure of the protein amyloid. We also are interested in using this structural information to design molecules which bind to amyloid (analogs of Congo red) and/or inhibit amyloid formation (conformationally-restrained peptide analogs). Finally, we hope to determine the sequence requirements for amyloid formation by comparing sequences from various amyloid-forming proteins.